COLARIS®: Hereditary Testing for Colorectal Cancer & Uterine Cancer
COLARIS® is a genetic test that assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine cancer. COLARIS® detects disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes that are responsible for the majority of Lynch syndrome and MYH-associated polyposis (MAP) cases.
Lynch syndrome, also known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC), is the most common of the hereditary colon cancer syndromes and is believed to account for 3% to 5% of all colorectal cancers. COLARIS® is a test for Lynch syndrome. Knowing the results may help patients and their physicians to take steps to prevent cancer before it has a chance to develop.
MYH-associated polyposis (MAP) is caused by mutations in the mutY homolog (MYH) gene. Individuals with MAP have mutations in both of their MYH genes (one from each parent, often referred to as “biallelic MYH mutations”). Patients often have no family history of colon cancer or polyps in parents (although siblings may be affected)83. The MYH gene is an important part of the base excision repair (BER) pathway, which allows for repair of DNA mutations caused by oxidative damage to cells.
Benefits of COLARIS® Testing
The results of the COLARIS test enable the development of a patient-specific medical management roadmap to significantly reduce the risk of cancer. COLARIS will help you to:
- Target increased surveillance and other interventions specifically to individuals with a Lynch Syndrome or MYH-associated polyposis (MAP) mutation(s) – personalizing patient care and increasing clinical efficiency
- Improve patient compliance with tailored screening recommendations and preventive measures
- Significantly improve outcomes and reduce medical costs through prevention, earlier diagnosis and treatment of cancer, should it develop
- Counsel patients and family members on the underlying cause of cancer in their family
- Avoid unnecessary interventions for family members who do not test positive for the mutation(s) known to be in the family
Medical Management and COLARIS®
Once a diagnosis of Lynch syndrome or MAP is confirmed, the following medical management options may help reduce the risk of cancer or detect cancer at an earlier, more treatable stage.
Colon Cancer (Lynch syndrome and MAP)
- Increased surveillance for colorectal cancer
- Surgical management of colorectal cancer
Endometrial and Ovarian Cancer (Lynch syndrome)
- Surveillance for endometrial and ovarian cancer
- Surgical management of endometrial and ovarian cancer
Surveillance for Other Lynch Syndrome-Related Cancers (Lynch syndrome)
- Upper GI endoscopy, urinalysis, physical examinations
For more information please contact us or visit https://myriad.com/products-services/hereditary-cancers/colaris/ or www.myriad-oncology.com